Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
BMRN heads into its October 27 earnings report with a striking disconnect: short sellers are rebuilding positions at the fastest rate in months, yet options traders are growing more bullish than at almost any point in the past year.
Short interest has climbed sharply, rising 17.7% over the past week to 6.1% of the free float, and the one-month gain of 16.2% confirms this is a sustained buildup rather than a single-session swing. That puts short interest at its highest level in the 30-day lookback window. The ORTEX short score nudged up to 44.8 this week, a small move but one that follows a step-change from the low 42s at the start of October, suggesting the bearish conviction is building gradually rather than arriving in one burst. Against all of that, borrowing costs remain trivial at 0.49%, and availability is abundant at 3,712%, meaning lenders have roughly 37 times the available shares relative to what has been borrowed. There is no squeeze pressure here; shorts are rebuilding in comfort.
Options positioning tells the opposite story. The put/call ratio has collapsed to 0.29, more than two standard deviations below its 20-day mean of 0.34, the most call-heavy reading in at least a year and close to the 52-week low of 0.28. The divergence between options traders piling into calls and short sellers adding to positions is the defining tension of this setup heading into the print. One side is wrong, or both are right for different time horizons.
The Street leans heavily bullish. Barclays raised its target to $114 from $111 this morning while holding its Overweight rating, and most recent analyst moves have been upward revisions rather than cuts. The mean price target sits at $91.73 against a current price of $54.38, a gap that reflects genuine disagreement rather than stale data: HC Wainwright maintains a Neutral at $60, essentially calling the stock fairly valued, while Jefferies, Piper Sandler and Canaccord all sit in the $90 to $114 range. The bull case centres on the Yuviwel settlement, which converts an achondroplasia competitor into a royalty stream adding an estimated $10 million to $90 million annually through 2030, while removing the Voxzogo litigation overhang entirely. Royalties are modelled on top of a Voxzogo base that generated $253 million in Q2 2026 alone. The bears point to a balance sheet carrying an estimated $3.5 billion of debt by end of Q3 2027 against roughly $1.9 billion of cash, and competitive risk from faster-than-expected Voxzogo share loss. Factor rankings are broadly supportive: EPS estimate revisions rank in the 96th percentile for 12-month forward growth, and analyst recommendation spread ranks 92nd, but the EPS surprise score is only in the 13th percentile, a reminder that beating estimates has not been a consistent habit.
Medicaid data from the Centers for Medicare and Medicaid Services adds one note of caution to the revenue picture. Medicaid units reimbursed were down 17% against Q1 last year, covering the period through January 2026. None of BMRN's alt data datasets have been measured as leading indicators of its reported figures, so this reading colours the backdrop rather than pointing to any particular outcome for the October print.
Institutional ownership offers some ballast. BlackRock reported a holding of 20.4 million shares as of September 30, worth roughly 10.6% of shares outstanding. FMR added 1.1 million shares in the most recent period, and State Street added 521,000. Vestal Point Capital built a position of 6 million shares in Q2, adding 2.45 million in that quarter alone. The insider picture is less encouraging: the only open-market transaction in the past 90 days was a $1.16 million sale by the Chief Legal Officer in September, not a 10b5-1 plan, though a single sale at that level is not alarming in isolation.
The stock is down 17% over the past month and off 3.3% this week, broadly in line with correlated peers: VRTX fell 3.4% on the week and INCY dropped 3.6%, while more speculative names like IMNM and OVID lost closer to 9%. BMRN is not underperforming its cohort materially, but the month-long slide has compressed the PE to 8.7 times and EV/EBITDA to 7.2 times, both down meaningfully over 30 days, which may explain why the options crowd is growing more interested in upside at these levels even as short sellers add to their books.
The October 27 print will determine which side of the options-versus-shorts argument gets vindicated, with the royalty contribution from the Yuviwel settlement and any update on Voxzogo market share the most closely watched line items.
See the live data behind this article on ORTEX.
Open BMRN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
